Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Intercept Makes No Changes To Ocaliva NASH Study Despite PBC Safety Issues

Data monitoring safety board okays continuation of pivotal REGENERATE study in non-alcoholic steatohepatitis despite deaths of patients receiving Ocaliva for primary biliary cholangitis.

Drug Safety Liver & Hepatic Clinical Trials

Bristol's Opdivo Diversifies Options In Liver Cancer

Response rate data supports yet another supplemental approval for Opdivo in an underserved tumor type that is becoming more competitive.

Approvals ImmunoOncology Cancer

SpringWorks Launches With $103m, Four Pfizer Drugs And A Focus On Underserved Patients

No disease is too small or too large for SpringWorks, which spun out Pfizer with four mid-/late-stage compounds to develop drugs in indications where patients have no good treatment options.

Financing Business Strategies StartUps and SMEs
Advertisement

Pharma Executives Need Convincing About Value-Based Contracts

Pharma company executives have limited experience with value-based contracts, but those that have experience are happy with them, says a new PwC report.

Pricing Debate Pricing Strategies Policy & Regulation


 Recent Tweets from Scrip


Commercial Explore this Topic

Portugal: An Uptick In Life Science VC Funding

An international VC, Vesalius Biocapital, is to invest in start-up life sciences and biotech companies in the western European country that is developing an entrepreneurial ecosystem.

Portugal Financing Commercial

Galderma Cuts Topical Derma R&D In Favor Of Systemic Treatments

Significant shifts in innovation for atopic dermatitis are behind the decision to close down the current R&D center of Nestlé group prescription dermatology business Galderma. The move affects around 550 employees in Sophia Antipolis, France, with only a small proportion likely to be offered jobs in a planned new center of excellence.

Dermatology Research and Development Strategies Companies

Medifron Move Signals Alzheimer’s R&D Acceleration In Korea

Medifron DBT's plan to make a sizable investment in its Alzheimer’s disease drug pipelines may be followed by further South Korean biotechs and pharmas accelerating development in the field as the country steps up support for dementia R&D.

South Korea Financing

Asia Executives To Watch: Takeda China GM; Wuxi NextCODE; Sosei

Takeda hires former Pfizer China executive as its new China GM; Wuxi NextCODE appoints its second COO in six months; Sosei appoints two VPs.

Appointments China

Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance

Emerging Company Profile: Partnered with Novartis on a nanoparticle candidate for type 1 diabetes, Parvus develops its proprietary Navacims to help the body’s immune system differ between a pathogen and itself.

StartUps and SMEs Business Strategies

Zai Lab Soars On Nasdaq Debut

Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.

Financing China

Venter's Synthetic Genomics Sued For Gender Discrimination

Synthetic Genomics, co-founded by genomic pioneer Craig Venter, has been sued by its former intellectual property chief for gender discrimination – a claim that CEO Oliver Fetzer believes to be "without merit."

Legal Issues Human Capital

Report: Women Eschew Life Science Companies That Lack Female Leadership

MassBio and Liftstream partnered on a report about women's, men's and companies' views on gender diversity in the life science industry and identified several opportunities for employers to improve, including the need to employ more women in leadership roles to attract female job-seekers.

Human Capital Leadership

Policy & Regulation Explore this Topic

Allergan Urgently Seeks FDA Guidance To Unblock Vraylar sNDA Review

In its initial assessment of Allergan's sNDA for Vraylar, the FDA has found the application - for treating negative symptoms associated with schizophrenia – wanting, and thus says it doesn't merit a full review.

Approvals Neurology United States

Medifron Move Signals Alzheimer’s R&D Acceleration In Korea

Medifron DBT's plan to make a sizable investment in its Alzheimer’s disease drug pipelines may be followed by further South Korean biotechs and pharmas accelerating development in the field as the country steps up support for dementia R&D.

South Korea Financing

Roche Racks Up Another RoActemra Green Light To Boost Revenues

The Swiss giant's blockbuster is the first non-steroid therapy approved in Europe for giant cell arteritis and the first major advance in treatment for over 50 years.

Immune Disorders Policy & Regulation

FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy

FDA's warning about 19 deaths related to excessive, off-label dosing for Ocaliva in primary biliary cholangitis spurs fears doctors will curtail prescribing and, worse, that the larger upcoming NASH market opportunity may be affected.

Drug Safety Liver & Hepatic

Research & Development Explore this Topic

Snapshot Of The Opioid Crisis, An Infographic

The opioid market is expected to total $18.4bn by 2020 – but the growing crisis of opioid abuse plagues manufacturers, policy makers and public health. Scrip takes a look at the pipeline of abuse-deterrent formulations and physician opinions about what impact those will have.

Neurology Drug Safety Market Intelligence

Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.

Clinical Trials Liver & Hepatic

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

VELOCITY Failure For Versartis's Lead Drug Sends Shares Into Tailspin

Versartis's long-acting growth hormone product missed Phase III non-inferiority endpoint, wiping more than 83% of the company's value.

Clinical Trials Companies
UsernamePublicRestriction

Register

Advertisement